Skip to main content
. 2024 Feb 25;115(4):1296–1305. doi: 10.1111/cas.16107

FIGURE 2.

FIGURE 2

Efficacy of tepotinib in Japanese patients. (A) Duration of response. (B) Progression‐free survival. (C) Overall survival. CI, confidence interval; DOR, duration of response; m, median; ne, not estimable; OS, overall survival; PFS, progression‐free survival.